RS59494B1 - Soli i polimorfi 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4, 3-cd]indol-6-ona - Google Patents
Soli i polimorfi 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4, 3-cd]indol-6-onaInfo
- Publication number
- RS59494B1 RS59494B1 RS20191394A RSP20191394A RS59494B1 RS 59494 B1 RS59494 B1 RS 59494B1 RS 20191394 A RS20191394 A RS 20191394A RS P20191394 A RSP20191394 A RS P20191394A RS 59494 B1 RS59494 B1 RS 59494B1
- Authority
- RS
- Serbia
- Prior art keywords
- azepino
- polymorphs
- indol
- methylamino
- tetrahydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30427710P | 2010-02-12 | 2010-02-12 | |
| EP16183844.6A EP3150610B1 (en) | 2010-02-12 | 2011-02-10 | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS59494B1 true RS59494B1 (sr) | 2019-12-31 |
Family
ID=43859823
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20161117A RS55487B1 (sr) | 2010-02-12 | 2011-02-10 | Soli i polimorfi 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona |
| RS20191394A RS59494B1 (sr) | 2010-02-12 | 2011-02-10 | Soli i polimorfi 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4, 3-cd]indol-6-ona |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20161117A RS55487B1 (sr) | 2010-02-12 | 2011-02-10 | Soli i polimorfi 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US8754072B2 (sr) |
| EP (4) | EP3597651A1 (sr) |
| JP (6) | JP5745283B2 (sr) |
| KR (2) | KR20120127495A (sr) |
| CN (2) | CN104876937B (sr) |
| AR (2) | AR080164A1 (sr) |
| AU (1) | AU2011213944B2 (sr) |
| CA (2) | CA3024216C (sr) |
| CY (3) | CY1118319T1 (sr) |
| DK (2) | DK2534153T3 (sr) |
| ES (2) | ES2753748T3 (sr) |
| HK (1) | HK1176617A1 (sr) |
| HR (2) | HRP20161742T1 (sr) |
| HU (3) | HUE047248T2 (sr) |
| IL (1) | IL220921B (sr) |
| LT (3) | LT3150610T (sr) |
| LU (1) | LUC00093I2 (sr) |
| MX (1) | MX343383B (sr) |
| NL (1) | NL300958I2 (sr) |
| NO (1) | NO2018039I1 (sr) |
| NZ (1) | NZ601445A (sr) |
| PL (2) | PL2534153T3 (sr) |
| PT (2) | PT3150610T (sr) |
| RS (2) | RS55487B1 (sr) |
| RU (1) | RU2570198C2 (sr) |
| SG (2) | SG10201406805RA (sr) |
| SI (2) | SI2534153T1 (sr) |
| SM (1) | SMT201600462B (sr) |
| TW (1) | TWI545123B (sr) |
| WO (1) | WO2011098971A1 (sr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2753748T3 (es) | 2010-02-12 | 2020-04-14 | Pfizer | Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona |
| TW201516636A (zh) * | 2013-10-22 | 2015-05-01 | Hon Hai Prec Ind Co Ltd | 電子裝置及其供電方法 |
| US9987285B2 (en) * | 2014-08-22 | 2018-06-05 | Clovis Oncology, Inc. | High dosage strength tablets of rucaparib |
| BR112018073667A2 (pt) | 2016-05-16 | 2019-03-12 | Pulmagen Therapeutics (Asthma) Limited | cristal de derivado de quinolina |
| DE102016218772A1 (de) * | 2016-09-28 | 2018-03-29 | Bruker Biospin Gmbh | Verbesserte Temperierung eines NMR-MAS-Rotors |
| KR20190110579A (ko) | 2017-01-24 | 2019-09-30 | 아시아 케미컬 인더스트리스 리미티드 | 루카파립 및 루카파립 염의 고체상 형태 |
| CN109651377B (zh) * | 2017-10-12 | 2020-10-20 | 成都海创药业有限公司 | 一种治疗癌症的化合物及其用途 |
| MX2020004545A (es) | 2017-11-03 | 2020-08-03 | Sandoz Ag | Sal cristralina de un inhibidor triciclico de poli(adp-ribosa)-polimerasa. |
| US11220507B2 (en) | 2017-12-15 | 2022-01-11 | Advitech Advisory And Technologies Sa | Process for the preparation of rucaparib and novel synthesis intermediates |
| WO2019130229A1 (en) | 2017-12-28 | 2019-07-04 | Mylan Laboratories Ltd | Methods and intermediates for preparing rucaparib |
| WO2019136298A1 (en) | 2018-01-05 | 2019-07-11 | Cybrexa, Inc. | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues |
| US10442813B2 (en) | 2018-01-30 | 2019-10-15 | RK Pharma Solutions LLC | Polymorphs of rucaparib camsylate and methods of making same |
| WO2019207498A1 (en) * | 2018-04-25 | 2019-10-31 | Biophore India Pharmaceuticals Pvt. Ltd | Solid forms of 8-fluoro-2-{4-[(methylamino)methyl] phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd] indol-6-one ((1s,4r)-7,7dimethyl-2-oxobicyclo [2.2.1] hept-1-yl) methanesulfonic acid salt (rucaparib camsylate) and the prerparation thereof |
| WO2019207596A1 (en) | 2018-04-25 | 2019-10-31 | Mylan Laboratories Limited | Novel crystalline forms of rucaparib (s)-camsylate salt and rucaparib free base |
| CN108743557A (zh) * | 2018-06-27 | 2018-11-06 | 李莉 | 一种磷酸瑞卡帕布软胶囊及其制备方法 |
| CN109111454A (zh) * | 2018-08-01 | 2019-01-01 | 宁波金未生物科技有限公司 | 一种瑞卡帕布s-樟脑磺酸盐 |
| CN111217818A (zh) * | 2018-11-27 | 2020-06-02 | 台耀化学股份有限公司 | 芦卡帕尼樟脑磺酸盐的结晶、及制备三环化合物、芦卡帕尼及其樟脑磺酸盐结晶的方法 |
| WO2020113500A1 (zh) * | 2018-12-06 | 2020-06-11 | 上海诚妙医药科技有限公司 | 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途 |
| CN114341162A (zh) | 2019-07-10 | 2022-04-12 | 赛博克萨2公司 | 作为治疗剂的细胞毒素的肽缀合物 |
| KR20220051332A (ko) | 2019-07-10 | 2022-04-26 | 싸이브렉사 3, 인크. | 치료제로서의 미세소관 표적화제의 펩티드 접합체 |
| CN111004244A (zh) * | 2019-12-27 | 2020-04-14 | 重庆市碚圣医药科技股份有限公司 | 一种瑞卡帕布樟脑磺酸盐的合成方法 |
| EP4100125A1 (en) | 2020-02-03 | 2022-12-14 | Sandoz AG | Polymorph of rucaparib mesylate |
| IL297218A (en) * | 2020-04-24 | 2022-12-01 | Astrazeneca Ab | Pharmaceutical formulations |
| US20230234938A1 (en) | 2020-04-28 | 2023-07-27 | Rhizen Pharmaceuticals Ag | Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors |
| AU2021304826A1 (en) | 2020-07-10 | 2023-02-02 | The Regents Of The University Of Michigan | GAS41 inhibitors and methods of use thereof |
| EP4182318A1 (en) | 2020-07-14 | 2023-05-24 | Assia Chemical Industries Ltd | Solid state forms of rucaparib salts |
| WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| WO2022215034A1 (en) | 2021-04-08 | 2022-10-13 | Rhizen Pharmaceuticals Ag | Inhibitors of poly(adp-ribose) polymerase |
| WO2023137060A1 (en) | 2022-01-11 | 2023-07-20 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib tosylate |
| WO2023152754A1 (en) * | 2022-02-08 | 2023-08-17 | Sawant, Mohit Manikrao | Crystalline form of rosuvastatin allyl ester |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4489011A (en) | 1983-05-16 | 1984-12-18 | Merrell Dow Pharmaceuticals Inc. | Hypoglycemic N-(2-substituted-3-dialkylamino-2-propenylidene)-N-alkylalkanaminium camsylate salts |
| GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
| GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| DE4125292A1 (de) * | 1991-07-31 | 1993-02-04 | Kali Chemie Pharma Gmbh | 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| CA2218503C (en) | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
| KR100489174B1 (ko) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
| JP3195756B2 (ja) | 1996-07-04 | 2001-08-06 | 公子 吉水 | 潤滑補助体 |
| EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| DE69716916T2 (de) | 1996-07-13 | 2003-07-03 | Glaxo Group Ltd | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
| BR9710362A (pt) | 1996-07-13 | 1999-08-17 | Glaxo Group Ltd | Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto |
| DE69712496T2 (de) | 1996-07-18 | 2002-08-29 | Pfizer | Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren |
| KR20000068248A (ko) | 1996-08-23 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 아릴설포닐아미노 하이드록삼산 유도체 |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| PT950059E (pt) | 1997-01-06 | 2004-10-29 | Pfizer | Derivados de sulfona ciclicos |
| US6303636B1 (en) | 1997-02-03 | 2001-10-16 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| AU5493598A (en) | 1997-02-07 | 1998-08-26 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
| BR9807678A (pt) | 1997-02-11 | 2000-02-15 | Pfizer | Derivados de ácidos arilsulfonil-hidroxâmicos |
| WO1998050356A1 (en) | 1997-05-07 | 1998-11-12 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| EP0984692A4 (en) | 1997-05-30 | 2001-02-21 | Merck & Co Inc | ANGIOGENESIS INHIBITORS |
| US5835420A (en) | 1997-06-27 | 1998-11-10 | Aplus Flash Technology, Inc. | Node-precise voltage regulation for a MOS memory system |
| CA2299355C (en) | 1997-08-08 | 2005-09-27 | Pfizer Products Inc. | Aryloxyarylsulfonylamino hydroxamic acid derivatives |
| DE69838172T2 (de) | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
| JP2001518470A (ja) | 1997-09-26 | 2001-10-16 | メルク エンド カムパニー インコーポレーテッド | 新規な血管形成阻害剤 |
| JP2001522853A (ja) | 1997-11-11 | 2001-11-20 | ファイザー・プロダクツ・インク | 抗癌剤として有用なチエノピリミジンおよびチエノピリジン誘導体 |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| JP4462654B2 (ja) | 1998-03-26 | 2010-05-12 | ソニー株式会社 | 映像素材選択装置及び映像素材選択方法 |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| WO1999061422A1 (en) | 1998-05-29 | 1999-12-02 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
| UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| EP1004578B1 (en) | 1998-11-05 | 2004-02-25 | Pfizer Products Inc. | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
| US6649645B1 (en) | 1998-12-23 | 2003-11-18 | Pharmacia Corporation | Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia |
| CA2356748A1 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia |
| AU781711B2 (en) * | 1999-01-11 | 2005-06-09 | Agouron Pharmaceuticals, Inc. | Tricyclic inhibitors of poly(ADP-ribose) polymerases |
| KR100452491B1 (ko) | 2001-03-29 | 2004-10-12 | 한미약품 주식회사 | 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법 |
| KR20040011751A (ko) | 2002-07-30 | 2004-02-11 | 씨제이 주식회사 | 암로디핀의 유기산염 |
| JP2006512355A (ja) | 2002-12-19 | 2006-04-13 | ファイザー・プロダクツ・インク | Ｅ−２−メトキシ−ｎ−（３−｛４−［３−メチル−４−（６−メチルピリジン−３−イルオキシ）−フェニルアミノ］−キナゾリン−６−イル｝−アリル）−アセトアミドの複合体、それらの製造方法および使用 |
| CA2520997A1 (en) | 2003-03-31 | 2004-10-14 | Stacie Sara Canan-Koch | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
| SI1660095T1 (sl) | 2003-07-25 | 2010-05-31 | Cancer Rec Tech Ltd | Triciklični parp inhibitorji |
| ES2337275T3 (es) * | 2004-09-22 | 2010-04-22 | Pfizer, Inc. | Procedimiento de preparacion de inhidores de poli(adp-ribosa)-polimrerasas. |
| MX2007002461A (es) | 2004-09-22 | 2008-03-13 | Pfizer | Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-{4-[metilamino)metil]fenil}-1, 3, 4, 5-tetrahidro-6h-azepino [5, 4, 3-cd]indol-6-ona. |
| CN101384264B (zh) * | 2004-09-22 | 2012-03-14 | 辉瑞大药厂 | 含有聚（adp-核糖）聚合酶抑制剂的治疗组合物 |
| MX2007003314A (es) | 2004-09-22 | 2007-08-06 | Pfizer | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas. |
| GB0502509D0 (en) | 2005-02-07 | 2005-03-16 | Pfizer Ltd | Novel salt form of a dopamine agonist |
| RU2404746C2 (ru) * | 2005-02-23 | 2010-11-27 | Тева Фармасьютикал Индастриз, Лтд. | Композиции разагилина с улучшенной однородностью содержимого |
| RU2009103658A (ru) * | 2006-07-05 | 2010-08-10 | Тева Фармасьютикал Индастриес Лтд. (Il) | Фармацевтические композиции мемантина |
| KR100843401B1 (ko) | 2006-12-04 | 2008-07-04 | 씨제이제일제당 (주) | 결정성 ｓ-(-)-암로디핀 캠실레이트 무수물 및 이의제조방법 |
| DK2091910T3 (en) * | 2006-12-06 | 2014-12-01 | Conatus Pharmaceuticals Inc | Crystalline forms of (3S) -3- [N- (N '- (2-tert-butylphenyl) oxamyl) alaninyl] amino-5- (2', 3 ', 5', 6'-tetrafluorophenoxy) -4-oxopentanoic acid |
| WO2008114114A2 (en) * | 2007-03-16 | 2008-09-25 | Pfizer Products Inc. | Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition |
| EP2065385A1 (en) | 2007-11-28 | 2009-06-03 | Laboratorios SALVAT, S.A. | Stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester |
| WO2009072915A1 (en) * | 2007-12-05 | 2009-06-11 | Bial - Portela & Ca., S.A. | New salts and crystal forms |
| KR20090060674A (ko) | 2007-12-10 | 2009-06-15 | 씨제이제일제당 (주) | 결정형의 지프라시돈 술폰산염, 그 제조방법, 및 그것를포함하는 약제학적 조성물 |
| CN106008460B (zh) | 2008-01-08 | 2022-08-12 | 默沙东公司 | 2-{4-[(3s)-哌啶-3-基]苯基}-2h-吲唑-7-羧酰胺的药学可接受的盐 |
| SG173002A1 (en) | 2009-01-17 | 2011-08-29 | Boomerang Systems Inc | Automated storage system and transport vehicle |
| ES2753748T3 (es) | 2010-02-12 | 2020-04-14 | Pfizer | Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona |
| CN107767647A (zh) | 2011-09-23 | 2018-03-06 | 金泰克斯公司 | 用于后视镜显示的系统和方法 |
| MY165747A (en) | 2011-12-26 | 2018-04-23 | Wintech Polymer Ltd | Polybutylene terephthalate resin pellets, and production method for said polybutylene terephthalate resin pellets |
| US9384339B2 (en) | 2012-01-13 | 2016-07-05 | Telecommunication Systems, Inc. | Authenticating cloud computing enabling secure services |
| US9672526B2 (en) | 2012-03-13 | 2017-06-06 | American Express Travel Related Services Company, Inc. | Systems and methods for tailoring marketing |
| KR101984831B1 (ko) | 2013-01-31 | 2019-05-31 | 삼성전자 주식회사 | 반도체 패키지 및 그 제조 방법 |
| CN103309115B (zh) | 2013-05-30 | 2016-03-23 | 京东方科技集团股份有限公司 | 彩色电泳显示面板及其制造方法、显示装置 |
| US9501163B2 (en) | 2014-05-06 | 2016-11-22 | Symbol Technologies, Llc | Apparatus and method for activating a trigger mechanism |
| US10884952B2 (en) | 2016-09-30 | 2021-01-05 | Intel Corporation | Enforcing memory operand types using protection keys |
| JP6943759B2 (ja) | 2017-12-28 | 2021-10-06 | 株式会社東海理化電機製作所 | シフト装置 |
-
2011
- 2011-02-10 ES ES16183844T patent/ES2753748T3/es active Active
- 2011-02-10 PL PL11708094T patent/PL2534153T3/pl unknown
- 2011-02-10 CN CN201410818193.1A patent/CN104876937B/zh active Active
- 2011-02-10 RU RU2012138892/04A patent/RU2570198C2/ru active
- 2011-02-10 HU HUE16183844A patent/HUE047248T2/hu unknown
- 2011-02-10 PT PT161838446T patent/PT3150610T/pt unknown
- 2011-02-10 WO PCT/IB2011/050571 patent/WO2011098971A1/en active Application Filing
- 2011-02-10 EP EP19178840.5A patent/EP3597651A1/en not_active Withdrawn
- 2011-02-10 LT LT16183844T patent/LT3150610T/lt unknown
- 2011-02-10 KR KR1020127023813A patent/KR20120127495A/ko active Search and Examination
- 2011-02-10 JP JP2011026718A patent/JP5745283B2/ja active Active
- 2011-02-10 KR KR1020197005968A patent/KR102108226B1/ko active IP Right Grant
- 2011-02-10 LT LTEP11708094.5T patent/LT2534153T/lt unknown
- 2011-02-10 EP EP11708094.5A patent/EP2534153B1/en active Active
- 2011-02-10 SG SG10201406805RA patent/SG10201406805RA/en unknown
- 2011-02-10 RS RS20161117A patent/RS55487B1/sr unknown
- 2011-02-10 CN CN201180009237.0A patent/CN102884066B/zh active Active
- 2011-02-10 PT PT117080945T patent/PT2534153T/pt unknown
- 2011-02-10 US US13/522,549 patent/US8754072B2/en active Active
- 2011-02-10 HU HUE11708094A patent/HUE030969T2/en unknown
- 2011-02-10 ES ES11708094.5T patent/ES2607806T3/es active Active
- 2011-02-10 NZ NZ601445A patent/NZ601445A/en unknown
- 2011-02-10 MX MX2012008911A patent/MX343383B/es active IP Right Grant
- 2011-02-10 SI SI201131051A patent/SI2534153T1/sl unknown
- 2011-02-10 AU AU2011213944A patent/AU2011213944B2/en active Active
- 2011-02-10 SG SG2012052171A patent/SG182533A1/en unknown
- 2011-02-10 DK DK11708094.5T patent/DK2534153T3/en active
- 2011-02-10 DK DK16183844T patent/DK3150610T3/da active
- 2011-02-10 RS RS20191394A patent/RS59494B1/sr unknown
- 2011-02-10 CA CA3024216A patent/CA3024216C/en active Active
- 2011-02-10 EP EP16183844.6A patent/EP3150610B1/en active Active
- 2011-02-10 SI SI201131808T patent/SI3150610T1/sl unknown
- 2011-02-10 EP EP22199074.0A patent/EP4166558A1/en active Pending
- 2011-02-10 PL PL16183844T patent/PL3150610T3/pl unknown
- 2011-02-10 CA CA2787881A patent/CA2787881C/en active Active
- 2011-02-11 AR ARP110100427A patent/AR080164A1/es not_active Application Discontinuation
- 2011-02-11 TW TW100104676A patent/TWI545123B/zh active
-
2012
- 2012-07-12 IL IL220921A patent/IL220921B/en active IP Right Grant
-
2013
- 2013-03-28 HK HK13103915.1A patent/HK1176617A1/zh unknown
-
2014
- 2014-05-08 US US14/272,589 patent/US9045487B2/en active Active
-
2015
- 2015-04-21 JP JP2015086722A patent/JP6013551B2/ja active Active
- 2015-04-28 US US14/698,463 patent/US9861638B2/en active Active
-
2016
- 2016-09-21 JP JP2016183846A patent/JP6371350B2/ja active Active
- 2016-12-13 CY CY20161101288T patent/CY1118319T1/el unknown
- 2016-12-19 HR HRP20161742TT patent/HRP20161742T1/hr unknown
- 2016-12-21 SM SM201600462T patent/SMT201600462B/it unknown
-
2017
- 2017-08-16 AR ARP170102290A patent/AR109356A2/es unknown
- 2017-12-06 US US15/833,073 patent/US10278974B2/en active Active
-
2018
- 2018-07-12 JP JP2018132270A patent/JP6640931B2/ja active Active
- 2018-11-13 CY CY2018031C patent/CY2018031I2/el unknown
- 2018-11-13 LU LU00093C patent/LUC00093I2/fr unknown
- 2018-11-14 HU HUS1800046C patent/HUS1800046I1/hu unknown
- 2018-11-15 LT LTPA2018517C patent/LTC2534153I2/lt unknown
- 2018-11-15 NO NO2018039C patent/NO2018039I1/no unknown
- 2018-11-19 NL NL300958C patent/NL300958I2/nl unknown
-
2019
- 2019-02-28 US US16/288,615 patent/US20200000821A1/en not_active Abandoned
- 2019-10-25 HR HRP20191944TT patent/HRP20191944T1/hr unknown
- 2019-10-31 CY CY20191101132T patent/CY1122218T1/el unknown
- 2019-12-26 JP JP2019235421A patent/JP2020050671A/ja not_active Withdrawn
-
2021
- 2021-05-06 JP JP2021078485A patent/JP2021107460A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS1800046I1 (hu) | 8-fluor-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-CD]indol-6-on sói és polimorfjai | |
| HK1257363A1 (zh) | 用於在聚合酶的抑制中使用的吡咯並嘧啶衍生物 | |
| EP2649060A4 (en) | PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES AND THEIR SALTS | |
| IL220154A0 (en) | Novel pyrimidine compounds as mtor and pi3k inhibitors | |
| ZA201202906B (en) | Novel naphthyridine derivatives and the use thereof as kinase inhibitors | |
| EP2244712A4 (en) | IN VIVO EXAMINATIONS OF CRYSTALLINE FORMS OF MELOXICAM | |
| EP2530079A4 (en) | PHENYL-C-GLUCOSIDE DERIVATIVES, PREPARATION METHODS AND USES THEREOF | |
| EG26275A (en) | Method to remove stains or dirt from the surface using citric acid | |
| PL2260029T3 (pl) | Otrzymywanie pochodnych morfoliny | |
| IL212070A (en) | Phenyl and pyridyl history of 7-piperidinoalkyl-4,3-dihydroquinolone | |
| HK1176556A1 (en) | N-9-substituted purine compounds, compositions and methods of use n-9- | |
| IL215865B (en) | Meloxicam formulation | |
| EP2701504A4 (en) | Sulindac derivatives, their use and preparation | |
| AP2013006816A0 (en) | Ptocess for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation | |
| ZA201008860B (en) | Pharmacokinetics of iontophorectic sumatriptan administration | |
| EP2636672A4 (en) | IMIDAZOLE DERIVATIVES AND PROCESS FOR THEIR MANUFACTURE AND USE | |
| GB2464854B (en) | Process for the preparation of risperidone | |
| EP2581375A4 (en) | IMPROVED METHODS FOR THE PREPARATION OF QUINOXALINE DERIVATIVES | |
| ZA201209693B (en) | Extended release formulation of pramipexole | |
| IL219860A0 (en) | Oral formulation for dexlansoprazole | |
| PL391018A1 (pl) | Sole pochodnych cystein i sposób wytwarzania soli pochodnych cystein | |
| GB0801288D0 (en) | Use of compounds for preparing anti-tuberculosis agents |